Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib rollover study in adults previously treated in a Blueprint Medicines avapritinib study
NL-OMON58642Phase 4Not yet recruiting
- Sponsor
- Blueprint Medicines
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of avapritinib in systemic mastocytosis (SM), sponsored by Blueprint Medicines. Primary endpoint: Long-term safety of avapritinib. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
avapritinib
03
Conditions
systemic mastocytosis (SM)
Beyond the preview
Go deeper on NL-OMON58642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58642.